Guideline recommendations for cangrelor should be upgraded : pros and cons
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology - 20(2024), 7 vom: 01. Apr., Seite e405-e407 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dangas, George [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
415SHH325A |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4244/EIJ-E-23-00070 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370515692 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370515692 | ||
| 003 | DE-627 | ||
| 005 | 20240404235329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4244/EIJ-E-23-00070 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM370515692 | ||
| 035 | |a (NLM)38562067 | ||
| 035 | |a (PII)EIJ-E-23-00070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dangas, George |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guideline recommendations for cangrelor should be upgraded |b pros and cons |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a cangrelor |2 NLM | |
| 650 | 7 | |a 6AQ1Y404U7 |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Purinergic P2Y Receptor Antagonists |2 NLM | |
| 700 | 1 | |a Nicolas, Johny |e verfasserin |4 aut | |
| 700 | 1 | |a Harbich, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Kurt |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology |d 2005 |g 20(2024), 7 vom: 01. Apr., Seite e405-e407 |w (DE-627)NLM185438652 |x 1969-6213 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2024 |g number:7 |g day:01 |g month:04 |g pages:e405-e407 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4244/EIJ-E-23-00070 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2024 |e 7 |b 01 |c 04 |h e405-e407 | ||